Today’s bio-pharma market is characterized by escalating uncertainty around policy-making and the Inflation Reduction Act.
How are CEOs and investors sizing up the current environment, and what should they be focused on now? Find out in the webcast recording below.
Jeff Kindler serves as the Executive Chairman for EntityRisk and is the former Chairman & CEO at Pfizer. Jeff is also a Senior Advisor to Blackstone, and an Operating Partner at Artis Ventures.
Dana Goldman is a co-founder and scientific advisor for EntityRisk. He is the Dean of the University of Southern California Sol Price School of Public Policy. He serves as co-director of the USC Schaeffer Center for Health Policy and Economics.